Tuberculosis (TB), often referred to as the 'silent killer,' continues to pose significant global health challenges. Despite advancements in healthcare, the ability to accurately diagnose TB remains a critical factor in controlling its spread and impact. This article aims to provide an in-depth review of contemporary diagnostic approaches for TB.
Microbiological tests, including sputum smear microscopy and culture methods, are the cornerstone of TB diagnosis. While smear microscopy is cost-effective and straightforward, its sensitivity is suboptimal. Culture methods, though more sensitive, are time-consuming and require sophisticated laboratories. The advent of rapid molecular tests, such as Xpert MTB/RIF, offers a promising alternative with high sensitivity and specificity, and the ability to detect rifampicin resistance.
The Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs) are used to identify latent TB infection. While TST is inexpensive and easy to administer, it lacks specificity in BCG-vaccinated individuals. IGRAs, though more specific, are expensive and not readily available in resource-limited settings.
Radiological techniques, such as chest X-rays and CT scans, are crucial in TB diagnosis, providing direct visualization of pulmonary abnormalities. However, these techniques lack specificity and cannot differentiate TB from other lung diseases. The integration of artificial intelligence in radiology is a promising frontier that could enhance TB detection.
While strides have been made in TB diagnosis, challenges persist. The choice of diagnostic method often depends on the balance between cost, availability, sensitivity, and specificity. The integration of novel technologies, such as rapid molecular tests and artificial intelligence, holds promise for improving TB diagnosis. Continuous research and innovation are essential to unmask this silent killer and reduce its global burden.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation